TheraRadar
Data updated: May 26, 2026

LEVOCARNITINE SF (levocarnitine)

Metabolic Approved 2019-08-14

LEVOCARNITINE SF is indicated for the treatment of Carnitine Deficiency; Reye-like Encephalopathy; Hypoglycemia; Cardiomyopathy; Inborn Error of Metabolism.

Source: FDA Label • NOVITIUM PHARMA
1
Indication
--
Phase 3 Trials
6
Years on Market

Details

Status
Prescription
First Approved
2019-08-14
Routes
ORAL
Dosage Forms
SOLUTION

Companies

Active Ingredient: LEVOCARNITINE

LEVOCARNITINE SF Approval History

2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2019 to 2019
Aug 2019 ORIGINAL
Update

What LEVOCARNITINE SF Treats

5 indications

LEVOCARNITINE SF is approved for 5 conditions since its original approval in 2019. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Carnitine Deficiency
  • Reye-like Encephalopathy
  • Hypoglycemia
  • Cardiomyopathy
  • Inborn Error of Metabolism
Source: FDA Label

LEVOCARNITINE SF Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to LEVOCARNITINE SF

3 of 10

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

CARNITOR
LEVOCARNITINE
5 shared
LEADIANT BIOSCI INC
Shared indications:
Carnitine DeficiencyReye-like EncephalopathyHypoglycemia +2 more
CARNITOR SF
LEVOCARNITINE
5 shared
LEADIANT BIOSCI INC
Shared indications:
Carnitine DeficiencyReye-like EncephalopathyHypoglycemia +2 more
LEVOCARNITINE
LEVOCARNITINE
5 shared
AM REGENT
Shared indications:
Carnitine DeficiencyReye-like EncephalopathyHypoglycemia +2 more
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT03953703 irb200020 Ph 2 completed Levocarnitine for Dry Eye in Sjogren's Syndrome
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

LEVOCARNITINE SF FDA Label Details

Indications & Usage

LEVOCARNITINE SF is indicated for the treatment of Carnitine Deficiency; Reye-like Encephalopathy; Hypoglycemia; Cardiomyopathy; Inborn Error of Metabolism.

Track LEVOCARNITINE SF with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.